Tina Lenasi
University of Helsinki
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tina Lenasi.
Proceedings of the National Academy of Sciences of the United States of America | 2009
Matjaz Barboric; Tina Lenasi; Hui Chen; Eric B. Johansen; Su Guo; B. Matija Peterlin
Eukaryotic gene expression is commonly controlled at the level of RNA polymerase II (RNAPII) pausing subsequent to transcription initiation. Transcription elongation is stimulated by the positive transcription elongation factor b (P-TEFb) kinase, which is suppressed within the 7SK small nuclear ribonucleoprotein (7SK snRNP). However, the biogenesis and functional significance of 7SK snRNP remain poorly understood. Here, we report that LARP7, BCDIN3, and the noncoding 7SK small nuclear RNA (7SK) are vital for the formation and stability of a cell stress-resistant core 7SK snRNP. Our functional studies demonstrate that 7SK snRNP is not only critical for controlling transcription elongation, but also for regulating alternative splicing of pre-mRNAs. Using a transient expression splicing assay, we find that 7SK snRNP disintegration promotes inclusion of an alternative exon via the increased occupancy of P-TEFb, Ser2-phosphorylated (Ser2-P) RNAPII, and the splicing factor SF2/ASF at the minigene. Importantly, knockdown of larp7 or bcdin3 orthologues in zebrafish embryos destabilizes 7SK and causes severe developmental defects and aberrant splicing of analyzed transcripts. These findings reveal a key role for P-TEFb in coupling transcription elongation with alternative splicing, and suggest that maintaining core 7SK snRNP is essential for vertebrate development.
RNA Biology | 2010
Tina Lenasi; Matjaz Barboric
Promoter-proximal pausing of RNA polymerase II (RNAPII) across the genome has renewed our attention to the early transcriptional events that control the establishment of pausing and the release of RNAPII into a productive transcription elongation. Here, we review our current understanding of the transcriptional cycle by RNAPII with a particular emphasis on the mechanisms that stimulate transcription elongation and cotranscriptional pre-mRNA splicing through an essential transcriptional kinase, the positive transcription elongation factor b (P-TEFb). We illustrate that by targeting a limited set of transcription elongation factors and paused RNAPII molecule during an early phase of transcription, P-TEFb unleashes an extensive crosstalk between transcription apparatus, RNA processing factors and chromatin for optimal production of mRNA.
Journal of Biological Chemistry | 2011
Tina Lenasi; B. Matija Peterlin; Matjaz Barboric
Promoter-proximal pausing of RNAPII coincides with the formation of the cap structure at the 5′ end of pre-mRNA, which is bound by the cap-binding protein complex (CBC). Although the positive transcription elongation factor b (P-TEFb) stimulates the release of RNAPII from pausing and promotes transcription elongation and alternative splicing by phosphorylating the RNAPII C-terminal domain at Ser2 (S2-P RNAPII), it is unknown whether CBC facilitates these events. In this study, we report that CBC interacts with P-TEFb and transcriptionally engaged RNAPII and is globally required for optimal levels of S2-P RNAPII. Quantitative nascent RNA immunoprecipitation and ChIP experiments reveal that depletion of CBC attenuates HIV-1 Tat transactivation and impedes transcription elongation of investigated CBC-dependent endogenous genes by decreasing the levels of P-TEFb and S2-P RNAPII, leading to accumulation of RNAPII in the body of these genes. Finally, CBC is essential for the promotion of alternative splicing through facilitating P-TEFb, S2-P RNAPII, and splicing factor 2/alternative splicing factor occupancy at a splicing minigene. These findings disclose a vital role of CBC in connecting pre-mRNA capping to transcription elongation and alternative splicing via P-TEFb.
Nucleic Acids Research | 2015
Kingsley M. Ekumi; Hana Paculova; Tina Lenasi; Vendula Pospichalova; Christian A. Bösken; Jana Rybarikova; Vitezslav Bryja; Matthias Geyer; Matjaz Barboric
The Cdk12/CycK complex promotes expression of a subset of RNA polymerase II genes, including those of the DNA damage response. CDK12 is among only nine genes with recurrent somatic mutations in high-grade serous ovarian carcinoma. However, the influence of these mutations on the Cdk12/CycK complex and their link to cancerogenesis remain ill-defined. Here, we show that most mutations prevent formation of the Cdk12/CycK complex, rendering the kinase inactive. By examining the mutations within the Cdk12/CycK structure, we find that they likely provoke structural rearrangements detrimental to Cdk12 activation. Our mRNA expression analysis of the patient samples containing the CDK12 mutations reveals coordinated downregulation of genes critical to the homologous recombination DNA repair pathway. Moreover, we establish that the Cdk12/CycK complex occupies these genes and promotes phosphorylation of RNA polymerase II at Ser2. Accordingly, we demonstrate that the mutant Cdk12 proteins fail to stimulate the faithful DNA double strand break repair via homologous recombination. Together, we provide the molecular basis of how mutated CDK12 ceases to function in ovarian carcinoma. We propose that CDK12 is a tumor suppressor of which the loss-of-function mutations may elicit defects in multiple DNA repair pathways, leading to genomic instability underlying the genesis of the cancer.
Future Virology | 2006
Xavier Contreras; Tina Lenasi; B. Matija Peterlin
Current therapies do not eradicate HIV from infected patients. Indeed, HIV hides in a latent form insensitive to these therapies. Thus, one priority is to purge these latent reservoirs. But what mechanisms are responsible for latency and what are the reservoirs of latently infected cells? The present knowledge in terms of HIV latency is still incomplete and current therapeutic strategies fail to eradicate completely latently infected cells. What could the future bring?
Wiley Interdisciplinary Reviews - Rna | 2013
Tina Lenasi; Matjaz Barboric
The generation of messenger RNA (mRNA) in eukaryotes is achieved by transcription from the DNA template and pre‐mRNA processing reactions of capping, splicing, and polyadenylation. Although RNA polymerase II (RNAPII) catalyzes the synthesis of pre‐mRNA, it also serves as a principal coordinator of the processing reactions in the course of transcription. In this review, we focus on the interplay between transcription and cotranscriptional pre‐mRNA maturation events, mediated by the recruitment of RNA processing factors to differentially phosphorylated C‐terminal domain of Rbp1, the largest subunit of RNAPII. Furthermore, we highlight the bidirectional nature of the interplay by discussing the impact of RNAPII kinetics on pre‐mRNA processing as well as how the processing events reach back to different phases of gene transcription. WIREs RNA 2013, 4:139–154. doi: 10.1002/wrna.1148
Clinical Cancer Research | 2017
Kingsley M. Ekumi; Hana Paculova; Tina Lenasi; Vendula Pospichalova; Christian A. Bösken; Jana Rybarikova; Vitezslav Bryja; Matthias Geyer; Matjaz Barboric
The Cdk12/CycK complex is a novel transcription elongation-associated kinase that promotes expression of a subset of RNA polymerase II (Pol II) genes, including those of the DNA damage response (DDR) network. CDK12 is mutated in many cancers, particularly in high-grade serous ovarian carcinoma (HGS-OvCa), where it is one of only nine genes with statistically recurrent somatic mutations. However, the influence of these mutations on the kinase and their link to cancerogenesis remain ill-defined. Here, we show that most CDK12 mutations interfere with formation of the complex, rendering the kinase inactive. By examining the mutations within the Cdk12/CycK structure, we find that they likely provoke structural rearrangements detrimental to Cdk12 activation. Our mRNA expression analysis of the patient samples containing the CDK12 mutations identifies coordinated down-regulation of key DDR genes, particularly those of the homologous recombination (HR) repair pathway. Moreover, we note that production of nascent HR gene transcripts is compromised significantly upon CDK12 and CYCK knockdown. Indeed, Cdk12 occupies these genes and promotes phosphorylation of the Pol II9s C-terminal domain (CTD) at Serine 2 (Ser2-P), the hallmark of effective transcription elongation, indicating that the down-regulated genes are directly controlled by Cdk12/CycK. Functionally, we demonstrate that the mutant Cdk12 proteins fail to stimulate the faithful repair of DNA double strand breaks via HR. In summary, we provide molecular basis of how mutated CDK12 ceases to function in ovarian carcinoma. We propose that CDK12 is a tumor suppressor of which the loss-of-function mutations could elicit defects in HR-mediated and possibly other DNA repair pathways, leading to genomic instability underlying the genesis of HGS-OvCa. Citation Format: Kingsley M. Ekumi, Hana Paculova, Tina Lenasi, Vendula Pospichalova, Christian A. Bosken, Jana Rybarikova, Vitezslav Bryja, Matthias Geyer, Dalibor Blazek and Matjaz Barboric. OVARIAN CARCINOMA CDK12 MUTATIONS IMPAIR GENE-SPECIFIC POL II ELONGATION AND FAITHFUL REPAIR OF DNA DOUBLE STRAND BREAKS [abstract]. In: Proceedings of the 11th Biennial Ovarian Cancer Research Symposium; Sep 12-13, 2016; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(11 Suppl):Abstract nr MIP-043.
RNA | 2006
Tina Lenasi; B. Matija Peterlin; Peter Dovč
Nature Structural & Molecular Biology | 2010
Matjaz Barboric; Tina Lenasi
Archive | 2011
Tina Lenasi; B. Matija Peterlin; Matjaz Barboric